Proteomics International Laboratories Ltd establishes a sales agency for medical devices in Europe

Perth, Australia (ABN Newswire) – Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics, is pleased to announce that it has engaged medical device sales agency Growth Medics BV to assist in the identification and selection of EU alliance partners for its PromarkerD predictive detection test diabetic kidney disease.

– Proteomics International engages sales agency Growth Medics BV in the recruitment and management of new PromarkerD partners and clients in Europe

– Growth Medics has a proven track record of helping medical device and diagnostics companies achieve market penetration and the digital marketing experience required as part of Proteomics International’s global go-to-market strategy

– Growth Medics are engaged on standard market terms, including a commission for achieving successful partnerships generating revenue for Proteomics International

– Across Europe, more than 61 million adults have type 2 diabetes, resulting in healthcare costs related to diabetes and its complications amounting to €176 billion across the region.

Growth Medics BV will help you identify, recruit and manage new partners and clients in Europe. Growth Medics is an international medical device sales accelerator with a proven track record of helping medical device and diagnostics companies achieve market penetration, as well as the digital marketing expertise required as part of Proteomics International’s global go-to-market strategy.

Growth Medics will also provide business development, marketing and administrative support to Proteomics International and PromarkerD from its office in the Netherlands. Their role will include attending trade shows on behalf of Proteomics International, customer service and training. Growth Medics will initially focus on new licensing and sales opportunities in the Netherlands, Belgium, Italy and Spain.

Diabetes is a “silent pandemic” and one of the major health challenges of our generation. Diabetic kidney disease (DKD) is a serious complication of diabetes that can lead to other health problems such as high blood pressure, heart disease, and ultimately kidney failure. In Europe, 61 million people suffer from diabetes. Total expenditure in the European region on advanced treatment of diabetes and its complications amounted to EUR 176 billion in 2021 (19.6% of global expenditure).

Proteomics International managing director Dr Richard Lipscombe said: “We believe Growth Medics is the ideal partner to launch PromarkerD in Europe due to their extensive market knowledge, proven track record, regulatory expertise and strong relationships with key stakeholders. Their multilingual and multicultural capabilities provide targeted sales and marketing strategies. This is a significant development in our PromarkerD expansion strategy in the diverse European market.

Growth Medics works with Proteomics International on a standard market fee-for-service basis, which includes a commission for establishing a successful partnership that generates revenue for Proteomics International to sell the PromarkerD test. Pursuant to the agreement, Proteomics International will not establish any similar sales agency in the Netherlands, Belgium, Italy and Spain. The engagement lasts two years and may be extended for additional three-month periods by mutual consent. Both parties have the right to terminate the engagement with six weeks’ notice in the event of breach of any material terms of the engagement. The order is also subject to standard conditions and guarantees typical of this type of contracts.

Growth Medics Managing Director, Emre Aykac, said: “With our expertise in the IVD (in vitro diagnostics) industry, we are excited to embark on this journey with Proteomics International to develop selected markets for PromarkerD in Europe and make this innovative solution available to patients. Anticipating DKD with four years in advance, our alliance aims to implement preventive measures that can save lives and improve the quality of care for patients across Europe.”

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication of diabetes that, if left untreated, can lead to dialysis or kidney transplantation. PromarkerD is a prognostic test that predicts future deterioration of kidney function in patients with type 2 diabetes and without pre-existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique “fingerprint” of early onset disease by measuring three serum protein biomarkers in combination with three routinely available conventional clinical variables (age, HDL cholesterol and estimated glomerular filtration rate (age, HDL cholesterol and estimated glomerular filtration rate). A cloud-based algorithm integrates results with the patient’s risk report. In clinical trials published in leading journals, PromarkerD correctly predicted up to 86% of healthy diabetics who would develop diabetic kidney disease within four years.

The PromarkerD test is a CE mark registered in the European Union. To visit the PromarkerD virtual stand, visit: https://www.PromarkerD.com/product

About GrowthMedics (www.growthmedics.com)

Growth Medics (Almelo, The Netherlands) is an ISO 13485 certified market development provider serving global medical device companies as they expand their international sales into European and Middle Eastern healthcare markets. Growth Medics’ mission is to enable global medical device manufacturers to achieve their international growth goals and unlock their full sales potential in healthcare markets in Europe, the Middle East and North Africa.

About Proteomics International Laboratories Ltd:

Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary of PILL, a medical technology company leading in predictive diagnostics and bioanalytical services. The company specializes in the area of proteomics – industrial-scale research on the structure and function of proteins. Proteomics International’s mission is to improve the quality of life by creating and applying innovative tools that enable better treatment of diseases.

Source:
Proteomics International Laboratories Ltd

Contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: [email protected]

Proteomics International (Europe)
T: +31 85 40 11 173
E: [email protected]

Dirk van Dissel 
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: [email protected]

Lisa Barnes
Public Relations
Profile Media
T: +61 416 583 672
E: [email protected]